Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis
ObjectiveThe aims of this study were to evaluate the quality of osteoporosis guidelines on traditional Chinese medicine (TCM) drug therapies and to analyze the specific recommendations of these guidelines.MethodsWe systematically collected guidelines, evaluated the quality of the guidelines using th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1276631/full |
| _version_ | 1827376026000293888 |
|---|---|
| author | Luan Zhang Luan Zhang Jiahui Li Jiahui Li Runsheng Xie Runsheng Xie Lingfeng Zeng Wenjia Chen Wenjia Chen Hui Li Hui Li Hui Li |
| author_facet | Luan Zhang Luan Zhang Jiahui Li Jiahui Li Runsheng Xie Runsheng Xie Lingfeng Zeng Wenjia Chen Wenjia Chen Hui Li Hui Li Hui Li |
| author_sort | Luan Zhang |
| collection | DOAJ |
| description | ObjectiveThe aims of this study were to evaluate the quality of osteoporosis guidelines on traditional Chinese medicine (TCM) drug therapies and to analyze the specific recommendations of these guidelines.MethodsWe systematically collected guidelines, evaluated the quality of the guidelines using the Appraisal of Guidelines Research and Evaluation (AGREE) II tool, and summarized the recommendations of TCM drug therapies using the Patient-Intervention-Comparator-Outcome (PICO) model as the analysis framework.Results and conclusionsA total of 20 guidelines were included. Overall quality evaluation results revealed that four guidelines were at level A, four at level B, and 12 at level C, whose quality needed to be improved in the domains of “stakeholder involvement”, “rigor of development”, “applicability” and “editorial independence”. Stratified analysis suggested that the post-2020 guidelines were significantly better than those published before 2020 in the domains of “scope and purpose”, “stakeholder involvement” and “editorial independence”. Guidelines with evidence systems were significantly better than those without evidence systems in terms of “stakeholder involvement”, “rigor of development”, “clarity of presentation” and “applicability”. The guidelines recommended TCM drug therapies for patients with osteopenia, osteoporosis and osteoporotic fracture. Recommended TCM drugs were mainly Chinese patent medicine alone or combined with Western medicine, with the outcome mainly focused on improving bone mineral density (BMD). |
| first_indexed | 2024-03-08T12:03:20Z |
| format | Article |
| id | doaj.art-1d18990a7e9a4518abd5ae2d459a4816 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-08T12:03:20Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-1d18990a7e9a4518abd5ae2d459a48162024-01-23T12:48:33ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-01-011410.3389/fendo.2023.12766311276631Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysisLuan Zhang0Luan Zhang1Jiahui Li2Jiahui Li3Runsheng Xie4Runsheng Xie5Lingfeng Zeng6Wenjia Chen7Wenjia Chen8Hui Li9Hui Li10Hui Li11The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaResearch Team of Chinese Medicine Standardization, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaResearch Team of Chinese Medicine Standardization, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaResearch Team of Chinese Medicine Standardization, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaResearch Team of Chinese Medicine Standardization, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaResearch Team of Chinese Medicine Standardization, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaResearch Team of Chinese Medicine Standardization, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaObjectiveThe aims of this study were to evaluate the quality of osteoporosis guidelines on traditional Chinese medicine (TCM) drug therapies and to analyze the specific recommendations of these guidelines.MethodsWe systematically collected guidelines, evaluated the quality of the guidelines using the Appraisal of Guidelines Research and Evaluation (AGREE) II tool, and summarized the recommendations of TCM drug therapies using the Patient-Intervention-Comparator-Outcome (PICO) model as the analysis framework.Results and conclusionsA total of 20 guidelines were included. Overall quality evaluation results revealed that four guidelines were at level A, four at level B, and 12 at level C, whose quality needed to be improved in the domains of “stakeholder involvement”, “rigor of development”, “applicability” and “editorial independence”. Stratified analysis suggested that the post-2020 guidelines were significantly better than those published before 2020 in the domains of “scope and purpose”, “stakeholder involvement” and “editorial independence”. Guidelines with evidence systems were significantly better than those without evidence systems in terms of “stakeholder involvement”, “rigor of development”, “clarity of presentation” and “applicability”. The guidelines recommended TCM drug therapies for patients with osteopenia, osteoporosis and osteoporotic fracture. Recommended TCM drugs were mainly Chinese patent medicine alone or combined with Western medicine, with the outcome mainly focused on improving bone mineral density (BMD).https://www.frontiersin.org/articles/10.3389/fendo.2023.1276631/fullguidelinesosteoporosisTCM drug therapiesquality evaluationstratified analysisrecommendations |
| spellingShingle | Luan Zhang Luan Zhang Jiahui Li Jiahui Li Runsheng Xie Runsheng Xie Lingfeng Zeng Wenjia Chen Wenjia Chen Hui Li Hui Li Hui Li Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis Frontiers in Endocrinology guidelines osteoporosis TCM drug therapies quality evaluation stratified analysis recommendations |
| title | Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis |
| title_full | Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis |
| title_fullStr | Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis |
| title_full_unstemmed | Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis |
| title_short | Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis |
| title_sort | osteoporosis guidelines on tcm drug therapies a systematic quality evaluation and content analysis |
| topic | guidelines osteoporosis TCM drug therapies quality evaluation stratified analysis recommendations |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1276631/full |
| work_keys_str_mv | AT luanzhang osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT luanzhang osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT jiahuili osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT jiahuili osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT runshengxie osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT runshengxie osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT lingfengzeng osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT wenjiachen osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT wenjiachen osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT huili osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT huili osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis AT huili osteoporosisguidelinesontcmdrugtherapiesasystematicqualityevaluationandcontentanalysis |